Download PDF
Zentralbl Chir 2002; 127(12): 1073-1077
DOI: 10.1055/s-2002-36467
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Risikoabschätzung beim Barrett-Ösophagus: Biomolekulare Marker und histopathologische Klassifikation

Risk estimation in Barrett’s esophagus: biomolecular marker and histopathologic classificationA. Walch1 , A. Schmitt-Gräff1 , H. Stein2 , M. Werner1
  • 1Universitätsklinikum Freiburg, Pathologisches Institut
  • 2Klinikum rechts der Isar, Technische Universität München
Further Information

Publication History

Publication Date:
03 January 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die histopathologische Diagnostik der intraepithelialen Neoplasie (früher „Dysplasie”) ist derzeit der Goldstandard für die Risikoabschätzung von Patienten mit einem Barrett-Ösophagus. Molekularbiologische und immunhistochemische Untersuchungen am Barrett-Ösophagus, die in der vorliegenden Übersichtsarbeit diskutiert werden, haben einen wesentlichen Beitrag zum Verständnis der Karzinogenese des Barrett-Karzinoms erbracht. Die Bedeutung neuer molekularbiologischer und immunhistochemischer Marker besteht darin, dass sie objektive ergänzende Informationen für solche diagnostisch und klinisch relevante Fragen bieten könnten, bei denen die Morphologie allein an ihren Grenzen angelangt ist. Dazu stehen derzeit jedoch nur wenige biomolekulare Marker zur Verfügung, die bislang nur in Einzelfällen hilfreich sind.

Abstract

The diagnosis of Barrett’s esophagus and the different degrees of intraepithelial neoplasia appear to be demanding in several aspects. Current data on genetic alterations involved in the carcinogenesis of Barrett’s esophagus are discussed. Several new biomarkers are being tested to help better to determine the risk of cancer development. However, a few immunohistochemical markers have emerged which could be helpful for the differential diagnosis of low- and high-grade intraepithelial neoplasia. Markers which could predict the progression of premalignant Barrett’s epithelium to carcinoma are still to be established. At present, the “goldstandard” for classifying the malignant potential in Barrett’s esophagus is the degree of intraepithelial neoplasia found on standard biopsy protocols.

Schlüsselwörter

Barrett-Ösophagus - intraepitheliale Neoplasie - Barrett- Karzinom - Molekularbiologie

Key words

Barrett’s esophagus - intraepithelial neoplasia - risk of cancer - molecularbiology

Literatur

  • 1 Bani-Hani K, Martin I G, Hardie L J, Mapstone N, Briggs J A, Forman D, Wild C P. Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma.  J Natl Cancer Inst. 2000;  92 1316-1321
    CrossrefPubMedGoogle Scholar
  • 2 Barrett M T, Sanchez C A, Galipeau P C, Neshat K, Emond M, Reid B J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett’s esophagus.  Oncogene. 1996;  13 1867-1873
    PubMedGoogle Scholar
  • 3 Caygill C P, Reed P I, Johnston B J, Hill M J, Ali M H, Levi S. A single centre’s 20 years’ experience of columnar-lined (Barrett’s) oesophagus diagnosis.  Eur J Gastroenterol Hepatol. 1999;  11 1355-1358
    PubMedGoogle Scholar
  • 4 Devesa S S, Blot W J, Fraumeni JF J r. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.  Cancer. 1998;  83 2049-2053
    CrossrefPubMedGoogle Scholar
  • 5 Faller G, Berndt R, Borchard F, Ell C, Fuchs K H, Geddert H, Gossner L, Günther T, Kirchner T, Koch H K, Langner C, Lüttges J, May A, Müller S, Oberhuber G, Seitz G, Stolte M, Tannapfel A, Vieth M, Walch A, Rüschoff J. Histopathologische Diagnostik der Barrett-Schleimhaut: Ergebnisse einer Konsensus-Konferenz der Arbeitsgemeinschaft Gastroenterologische Pathologie der Deutschen Gesellschaft für Pathologie am 22. September 2001 in Erlangen. (Manuskript in Vorbereitung)
    Google Scholar
  • 6 Fitzgerald R C, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett’s esophagus.  Dig Dis. 1998;  16 63-80
    CrossrefPubMedGoogle Scholar
  • 7 Flejou J F, Doublet B, Potet F, Metayer J, Hemet J. DNA ploidy in adenocarcinoma of Barrett’s esophagus.  Ann Pathol. 1990;  10 161-165
    PubMedGoogle Scholar
  • 8 Galipeau P C, Cowan D S, Sanchez C A, Barrett M T, Emond M J, Levine D S, Rabinovitch P S, Reid B J. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett’s esophagus.  Proc Natl Acad Sci USA. 1996;  93 7081-7084
    CrossrefPubMedGoogle Scholar
  • 9 Herbst J J, Berenson M M, McCloskey D W, Wiser W C. Cell proliferation in esophageal columnar epithelium (Barrett’s esophagus).  Gastroenterology. 1978;  75 683-687
    PubMedGoogle Scholar
  • 10 Hong M K, Laskin W B, Herman B E, Johnston M H, Vargo J J, Steinberg S M, Allegra C J, Johnston P G. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus.  Cancer. 1995;  75 423-429
    PubMedGoogle Scholar
  • 11 Jankowski J, Coghill G, Tregaskis B, Hopwood D, Wormsley K G. Epidermal growth factor in the oesophagus.  Gut. 1992;  33 1448-1453
    PubMedGoogle Scholar
  • 12 Jankowski J. Altered gene expression of growth factors and their receptors during esophageal tumorigenesis.  Gastroenterol Clin Biol. 1994;  18 40-45
    PubMedGoogle Scholar
  • 13 Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett’s esophagus.  Gastroenterology. 1998;  115 1381-1386
    PubMedGoogle Scholar
  • 14 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.  N Engl J Med. 1999;  340 825-831
    CrossrefPubMedGoogle Scholar
  • 15 Millikan K W, Mall J W, Myers J A, Hollinger E F, Doolas A, Saclarides T J. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?.  Am Surg. 2000;  66 401-406
    PubMedGoogle Scholar
  • 16 Morris C D, Armstrong G R, Bigley G, Green H, Attwood S E. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence.  Am J Gastroenterol. 2001;  96 990-996
    PubMedGoogle Scholar
  • 17 Muzeau F, Flejou J F, Thomas G, Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers.  Int J Cancer. 1997;  72 27-30
    CrossrefPubMedGoogle Scholar
  • 18 Nakamura T, Nekarda H, Hoelscher A H, Bollschweiler E, Harbeck N, Becker K, Siewert J R. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus.  Cancer. 1994;  73 1785-1794
    PubMedGoogle Scholar
  • 19 Pellish L J, Hermos J A, Eastwood G L. Cell proliferation in three types of Barrett’s epithelium.  Gut. 1980;  21 26-31
    PubMedGoogle Scholar
  • 20 Reid B J, Levine D S, Longton G, Blount P L, Rabinovitch P S. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.  Am J Gastroenterol. 2000;  95 1669-1676
    PubMedGoogle Scholar
  • 21 Riegman P H, Vissers K J, Alers J C, Geelen E, Hop W C, Tilanus H W, van Dekken H. Genomic alterations in malignant transformation of Barrett’s esophagus.  Cancer Res. 2001;  61 3164-3170
    PubMedGoogle Scholar
  • 22 Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert H E. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus.  Am J Clin Pathol. 2001;  115 835-840
    CrossrefPubMedGoogle Scholar
  • 23 Shirvani V N, Ouatu-Lascar R, Kaur B S, Omary M B, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.  Gastroenterology. 2000;  118 487-496
    PubMedGoogle Scholar
  • 24 Souza R F, Shewmake K, Beer D G, Cryer B, Spechler S J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.  Cancer Res. 2000;  60 5767-5772
    PubMedGoogle Scholar
  • 25 Steinbach G, Lynch P M, Phillips R K, Wallace M H, Hawk E, Gordon G B, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L K, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med. 2000;  342 1946-1952
    CrossrefPubMedGoogle Scholar
  • 26 Walch A, Bink K, Hutzler P, Bowering K, Letsiou I, Zitzelsberger H, Braselmann H, Stein H, Hofler H, Werner M. Sequential multilocus fluorescence in situ hybridization can detect complex patterns of increased gene dosage at the single cell level in tissue sections.  Lab Invest. 2001;  81 1457-1459
    PubMedGoogle Scholar
  • 27 Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M, Aubele M, Stein H, Siewert J R, Hofler H, Werner M. Her-2/neu Gene Amplification, Elevated mRNA Expression, and Protein Overexpression in the Metaplasia-Dysplasia-Adenocarcinoma Sequence of Barrett’s Esophagus.  Lab Invest. 2001;  81 791-801
    PubMedGoogle Scholar
  • 28 Walch A, Zitzelsberger H, Bruch J, Keller G, Angermeier D, Aubele M, Mueller M, Stein H, Braselmann H, Siewert J R, Höfler H, Werner M. Chromosomal imbalances in Barrett’s adenocarcinoma and in the metaplasia-dysplasia-carcinoma-sequence.  Am J Pathol. 2000;  156 555-566
    PubMedGoogle Scholar
  • 29 Werner M, Flejou J F, Hainaut P, Höfler H, Lambert R, Keller G, Stein H J. Adenocarcinoma of the oesophagus. In: Aaltonen LA, Hamilton S, Kleihues P, Sobin LH (eds). WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Springer-Verlag, Berlin 2000: 16-22
    Google Scholar
  • 30 Werner M, Mueller J, Walch A, Hofler H. The molecular pathology of Barrett’s esophagus.  Histol Histopathol. 1999;  14 553-559
    PubMedGoogle Scholar
  • 31 Wilson K T, Fu S, Ramanujam K S, Meltzer S J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas.  Cancer Res. 1998;  58 2929-2934
    PubMedGoogle Scholar
  • 32 Yacoub L, Goldman H, Odze R D. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett’s-associated neoplasia: correlation with prognosis.  Mod Pathol. 1997;  10 105-112
    PubMedGoogle Scholar

Dr. med. Axel Walch

Pathologisches Institut

Ludwig- Aschoff-Haus

Albertstraße 19

79002 Freiburg

Phone: 07 61/2 03-67 37

Fax: 07 61/2 03-67 90

Email: walch@ukl.uni-freiburg.de

      >